Visit Lonza at CPHI Worldwide 2024 in Milan at Stand 6A2. CPHI serves as a platform for networking, collaboration, and showcasing the latest innovations and technologies in the pharmaceutical sector. Attendees will have the chance to connect with industry leaders, discover new trends and gain valuable insights.


Divisions: Biologics, Small Molecules, Cell & Gene, Capsules & Health Ingredients
Date: October 8-10, 2024
Booth: Stand 6A2
Location: Milan, Italy
Join us for an engaging speaking session

Pioneering Capsule Innovation: Accelerating Oral and Inhalable Drug Delivery

Explore Lonza's new innovation center, dedicated to accelerating capsule development for oral and pulmonary drug delivery. Join us to discover how we foster collaboration with customers and co-innovation in a cutting-edge environment where science meets ingenuity. Learn how our expert team tackles complex formulation challenges, navigates global regulatory requirements, and supports your journey from concept to market. Experience how Lonza can partner with you to redefine the future of pharmaceutical excellence.

Speakers

Meeta Kratz
Global Vice President of Strategic Growth & Revenue Management
Lonza Capsules & Health Ingredients

Dr. Camille Dumont
Manager Customer Application, Capsule Application Lab
Lonza Capsules & Health Ingredients

Details

Wednesday, 9 October 2024
2:45pm - 3:10pm
Integrated Pharma Theatre Hall 22

 

Add to calendar

Understanding the Problem of Decarbonization in Drug Delivery

Join us for a focused session exploring the emission drivers behind different drug delivery methods like capsules, inhalers, and injectables. Harmonized parallel assessment helps you to understand commonalities and differences on the path towards sustainable products:

  • Capsules
  • Inhalers
  • Injectables

Lonza Panelist

Christine Lebault

Head of Procurement CHI and Small Molecules


Pharma’s Innovation Catalyst: How Partnerships, Investments, and Acquisitions are Shaping Healthcare's Future

Pharma is often perceived as lacking innovation outside its core R&D operations. However, partnerships, investments, and acquisitions are crucial in driving innovation and tackling significant healthcare challenges. Join this panel discussion to gain the latest insights into the pharmaceutical industry's current investment and acquisition dynamics.

Lonza Panelist

Jan Vertommen

Vice President, Head of Commercial Development


Knowledge Center
Related Insights
Small Molecules Inhalation
Webinar (on-demand)
Dry Powder Inhalable Vaccines for Shelf Stability and Global Access
What if a formulation were possible that removed the need for cold chain distribution? There is a significant need for shelf-stable vaccines that are...
Andrea Cubitt, Ph.D., Vice President External Scientific Alliances and Intellectual Property, aTyr Pharma
Article
A Small Biotech Recognizes the Importance in How You Think of Manufacturing in Selecting a CDMO
Manufacturing is crucial to the success of any drug development project but is too often overlooked. Dr. Andrea Cubitt, VP of External Scientific...
SM drug product
Webinar (on-demand)
CMC and CDMO: The Importance of Choosing the Right Partner
Small pharma companies are driving pipeline innovation and are increasingly taking more complex small molecules further down the development pipeline,...
White paper
The Early Advantage for IND Success and Beyond
Many of the decisions made during the early days of building and compiling the manufacturing information for your IND submission will directly impact...
lab workers on tablet
e-book
Accelerating Small Molecule Advancements
The increasing number of breakthroughs in small molecule drug development are exciting, but corresponding workflows are complex and require much more...
lab workers on tablet
e-book
Leveraging Advanced Analytical Tools to De-risk Pharmaceutical Development
Drug development continues to advance understanding about causes of disease, as well as to innovate therapeutic modalities. Yet, the process remains...
Low Solubility Playbook
e-book
Drug Solubility and the Need for Speed
A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find...
Visit Knowledge Center